Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$6.45M-$6.45MderivedN/M vs Q4 2019 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$6,089,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,382,000N/M Free Cash Flowderived-$6,381,000N/M ended Dec 31, 2020 · filed Mar 31, 2021 · 90 d after period end